The changing and dynamic epidemiology of meningococcal disease

Vaccine

Volumn 30, Issue SUPPL. 2, 2012, Pages

  Halperin, Scott A ^a   Bettinger, Julie A ^b   Greenwood, Brian ^c   Harrison, Lee H ^d   Jelfs, Jane ^e   Ladhani, Shamez N ^f   McIntyre, Peter ^e   Ramsay, Mary E ^f   Sáfadi, Marco A P ^g  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e NATIONAL CENTRE FOR IMMUNISATION RESEARCH AND SURVEILLANCE   (Australia)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Epidemiology; Meningococcus; Neisseria meningitidis; Surveillance

Indexed keywords

MENINGOCOCCUS VACCINE;

AFRICA; ARTICLE; DISEASE CONTROL; DISEASE SURVEILLANCE; HUMAN; INCIDENCE; MASS IMMUNIZATION; MENINGITIS; MENINGOCOCCOSIS; NEISSERIACEAE; NEW ZEALAND; NORTH AFRICA; PRIORITY JOURNAL; VACCINATION;

HUMANS; INCIDENCE; MENINGITIS, BACTERIAL; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; SEPSIS; WORLD HEALTH;

EID: 84861117523     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.032     Document Type: Article

References (111)

1. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl. 2):B51-B63.
2. Perkins B.A., Stephens D.S., Popovic T., Hughes J.M. Meningococcal disease. N Engl J Med 2001, 344:1378-1388.
3. Hausdorff W.P., Hajjeh R., Al-Mazrou A., Shibl A., Soriano-Gabarro M. The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) Region-Current status and needs. Vaccine 2007, 25(11):1935-1944.
4. El-Akkad A.M. Epidemiology of cerebrospinal meningitis in Egypt during the last 50 years. J Egypt Public Health Assoc 1969, 44(4):260-279.
5. Nakhla I., Frenck R.W., Teleb N.A., El Oun S., Sultan Y., Mansour H., et al. The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt. Vaccine 2005, 23(25):3288-3293.
6. World Health Organization. WHO-Multi-Disease Surveillance Centre Ouagadougou, Regional Meningitis Surveillance, <> [accessed 20.10.11]. http://www.who.int/csr/disease/meningococcal/epidemiological/en/index.html.
7. Collard J-M., Maman Z., Yacouba H., Djibo S., Nicolas P., Jusot J.-F., et al. Increase in Neisseria meningitidis serogroup W135, Niger, 2010 [letter]. Emerg Infect Dis 2010, 16(9):1496-1498.
8. LaForce F.M., Ravenscroft N., Djingarey M., Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009, 27(Suppl. 2):B13-B19.
9. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364(24):2293-2304.
10. Meningitis Vaccine Project. Dramatic fall in cases of meningitis A in three West African nations after new vaccine introduction, <> [accessed 20.10.11]. http://www.meningvax.org/files/PR_MenAfriVacimpact_9June2011_EN.pdf.
11. Mutonga D.M., Pimentel G., Muindi J., Nzioka C., Mutiso J., Klena J.D., et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. Am J Trop Med Hyg 2009, 80(4):619-624.
12. WHO Meningococcal disease, Uganda - update. Wkly Epidemiol Rec 2006, 81:62.
13. Pelkonen T., Roine I., Monteiro L., Joao Simoes M., Anjos E., Pelerito A., et al. Acute childhood bacterial meningitis in Luanda, Angola. Scand J Infect Dis 2008, 40(11-12):859-866.
14. Roca A., Bassat Q., Morais L., Machevo S., Sigaúque B., O'Callaghan C., et al. Surveillance for acute bacterial meningitis among children admitted to a district hospital in rural Mozambique. Clin Infect Dis 2009, 48(Suppl. 2):S172-S180.
15. McCormick D.W., Molyneux E.M. Bacterial meningitis and Haemophilus influenzae type b conjugate vaccine, Malawi. Emerg Infect Dis 2011, 17(4):688-690.
16. Bercion R., Bobossi-Serengbe G., Gody J.C., Beyam E.N., Manirakiza A., Le Faou A. Acute bacterial meningitis at the 'Complexe Pédiatrique' of Bangui, Central African Republic. J Trop Pediatr 2008, 54(2):125-128.
17. Von Gottberg A., du Plessis M., Cohen C., Prentice E., Schrag S., de Gouveia L., et al. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis 2008, 46(3):377-386.
18. Cohen C., Singh E., Wu H.M., Martin S., de Gouveia L., Klugman K.P., et al. Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS 2010, 24(9):1351-1360.
19. de Gouveia L., von Gottberg A Neisseria meningitidis. Commun Dis Surveill Bull 2011, 9(2):45-47.
20. Ibarz-Pavón A.B., Morais L., Sigaúque B., Mandomando I., Bassat Q., Nhacolo A., et al. Epidemiology, molecular characterisation and antibiotic resistance of Neisseria meningitidis from patients ≤15 years in Manhiça, rural Mozambique. PloS One 2011, 6(6):e19717.
21. Vyse A., Wolter J.M., Chen J., Ng T., Soriano-Gabarro M. Meningococcal disease in Asia: an under-recognised public health burden. Epidemiol Infect 2011, 139:967-985.
22. Sinclair D., Preziosi M-P., Jacob John T., Greenwood B. The epidemiology of meningocccal disease in India. Trop Med Int Health 2010, 15(12):1421-1435.
23. Oberti J., Hoi N.T., Caravano R., Tan C.M., Roux J. Etude d'une épidémie de méningococcie au Viet Nam (provinces du sud). Bull World Health Org 1981, 59(4):585-590.
24. Whittle H.C., Evans-Jones L.G., Onyewotu I., Adjukiewicz A., Turunen U., Crockford J., et al. Group-C meningococcal meningitis in the northern savanna of Africa. Lancet 1975, 1(7921):1377.
25. Broome C.V., Rugh M.A., Yada A.A., Giat L., Giat H., Zeltner J.M., et al. Epidemic group C meningococcal meningitis in Upper Volta, 1979. Bull World Health Org 1983, 61(2):325-330.
26. Hu X.J. Study on periodically prevalent feature for epidemic cerebrospinal meningitis in China. Chin J Epidemiol 1991, 12:136-139. [in Chinese].
27. Ni J.D., Jin Y.H., Dai B., Wang X.P., Liu D.Q., Chen X., et al. Recent epidemiological changes in meningocccal disease may be due to the dispalacment of serogroup A by serogroup C in Hefei city, China. Postgrad Med J 2008, 84(988):87-92.
28. Nair D., Dawar R., Deb N., Capoor M.R., Singal S., Upadhayay D.J., et al. Outbreak of meningococcal disease in and around New Delhi, India, 2005-2006: a report from a tertiary care hospital. Epidemiol Infect 2009, 137(4):570-576.
29. World Health Organization. Epidemic and pandemic alert and response (EPR). Meningococcal disease in the Philippines - update <>; 2005. http://www.who.int/csr/don/2005_01_28a/en/index.html.
30. Hossain M.A., Ahmed D.A., Ahmed T., Islam N., Breiman R.F. Short report: increasing isolations of Neisseria meningitidis serogroup A from blood and cerebrospinal fluid in Dhaka, Bangladesh, 1999-2006. Am J Trop Med Hyg 2009, 80(4):615-618.
31. Wilder-Smith A., Chow A., Goh K.T. Emerence and disapapearance of W135 meningococcal disease. Epidemiol Infect 2010, 138(7):976-978.
32. Patel P.T. Cerebrospinal fever in Bombay. A study of 170 consecutive cases during the years 1921-1924. Lancet 1926, 11:539-541.
33. Australian Meningococcal Surveillance Programme Annual report of the Australian Meningococcal Surveillance Programme, 2009. Commun Dis Intell 2010, 34(3):291-302.
34. Australian Government Department of Health and Ageing Communicable Diseases Surveillance: National Notifiable Diseases Surveillance System. Commun Dis Intell 2010, 34(3):214-216.
35. Chiu C., Dey A., Wang H., Menzies R., Deeks S., Mahajan D., et al. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell 2010, 34(Suppl):S81-S83.
36. Patel M.S., Merianos A., Hanna J.N., Vartto K., Tait P., Morey F., et al. Epidemic meningococcal meningitis in central Australia, 1987-1991. Med J Aust 1993, 158:336-340.
37. Trotter C., Gay N., Edmunds W. Dynamic models of meningococcal carriage and the impact of serogroup C conjugate vaccination. Am J Epidemiol 2005, 162:89-100.
38. de Greeff S.C., de Melker H.E., Spanjaard L., Schouls L.M., van Der Ende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006, 25(1):79-80.
39. Kinlin L.M., Jamieson F., Brown E.M., Brown E.S., Rawte P., Dolman S., et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine 2009, 27:1735-1740.
40. De Wals P., Deceuninck G., Lefebvre B., Boulianne N., De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine: A 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J 2011, 30(7):566-569.
41. Simpkins D., Wood N., Jelfs J., McIntyre P.B., Menzies R., Lawrence G., et al. Modern trends in mortality from meningococcal disease in Australia. Pediatr Infect Dis J 2009, 28(12):1119-1120.
42. Martin D.R., Walker S.J., Baker M.G., Lennon D. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Inf Dis 1998, 177:497-500.
43. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23:2191-2196.
44. Oster P., O'Hallahan J., Aaberge I., Tilman S., Ypma E., Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007, 25:3075-3079.
45. Lopez L., Sexton K., Carter P. The epidemiology of meningococcal disease in New Zealand in 2010 2011, Institute of Environmental Science and Research Ltd. (ESR), Wellington, New Zealand, Available at: www.surv.esr.cri.nz/PDF_surveillance/MeningococcalDisease/2010/2010AnnualRpt.pdf [accessed September 2011].
46. Kelly C., Arnold R., Galloway Y., O'Hallahan J. A prospective study of the effectiveness of New Zealand meningococcal B vaccine. Am J Epidemiol 2007, 166:817-823.
47. Arnold R., Galloway Y., McNicholas A., O'Hallahan J. Effectiveness of a vaccination programme for and epidemic of meningococcal B in New Zealand. Vaccine 2011, 29(40):7100-7106.
48. Jackson C., Lennon D., Wong S., Yan J., Stewart J., Reid S., et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Child 2011, 96:744-751.
49. European Centre for Disease Prevention and Control Surveillance of invasive bacterial diseases in Europe 2008/2009, Stockholm: ECDC; 2011. Available at: <> [accessed 04.10.11]. http://ecdc.europa.eu/en/activities/diseaseprogrammes/vpd/Pages/index.aspx.
50. Granoff D.M. Review of meningococcal group B vaccines. Clin Infect Dis 2010, 50(Suppl. 2):S54-S65.
51. Flood J, Ladhani S, Campbell H, Borrow R, Gray SJ, Marsh WJ, et al. P 043. The epidemiology of invasive meningococcal disease in England and Wales: implications for potential infant immunisation schedules (page 124-5).
52. Levy C., Taha M.K., Weil O.C., Quinet B., Lecuyer A., Alonso J.M., et al. Association of meningococcal phenotypes and genotypes with clinical characteristics and mortality of meningitis in children. Pediatr Infect Dis J 2010, 29:618-623.
53. Hershey J.H., Hitchcock W. Epidemiology and meningococcal serogroup distribution in the United States. Clin Pediatr (Phila) 2010, 49:519-524.
54. Campbell H., Andrews N., Borrow R., Trotter C., Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010, 17(May (5)):840-847.
55. Ishola D, Borrow R, Findlow H, Trotter C, Ramsay M. P 068. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England, a decade after vaccine introduction (pages 174-5). The 11th European Meningococcal Group Meeting (EMGM) Congress 2011: Ljubljana, Slovenia, Abstract available at: <> [accessed 04.10.11]. http://emgm.eu/meetings/emgm2011/abstracts.pdf.
56. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network, Neisseria meningitidis, 2009. Available at: <>; 2010 [accessed 04.10.11]. http://www.cdc.gov/abcs/reports-findings/survreports/mening09.pdf.
57. Jacobsson S, Mölling P, Thulin Hedberg S, Lepp T, Unemo M, Fredlund H, et al. P006. Invasive meningococcal disease in Sweden, 2010 (Page 45-6). The 11th European Meningococcal Group Meeting (EMGM) Congress 2011: Ljubljana, Slovenia, Abstract available at: <> [accessed 04.10.11]. http://emgm.eu/meetings/emgm2011/abstracts.pdf.
58. Thulin Hedberg S., Törös B., Fredlund H., Olcén P., Mölling P. Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveill 2011, 16(23):8-14.
59. Caugant DA, Løvoll Ø, Blystad H. P040. Meningococcal disease in Norway, 2009-2010: emergence of serogroup Y. EMGM (Pages 117-8). The 11th European Meningococcal Group Meeting (EMGM) Congress 2011: Ljubljana, Slovenia. Abstract available at: <> [accessed 04.10.11]. http://emgm.eu/meetings/emgm2011/abstracts.pdf.
60. Vainio A, Toropainen M, Kuusi M, Virolaine A. P 037. Characteristics of invasive meningococcal serogroup Y isolates in Finland, 1995-2010 (Pages 111-2). The 11th European Meningococcal Group Meeting (EMGM) Congress 2011: Ljubljana, Slovenia. Abstract available at: <> [accessed 04.11.11]. http://emgm.eu/meetings/emgm2011/abstracts.pdf.
61. Ladhani SN, Lucidarme J, Newbold LS, Gray SJ, Carr AD, Findlow J, et al. Invasive meningococcal capsular Y disease, England and Wales, 2007-2009. Emerg Infect Dis, 2012 Jan. doi:10.3201/eid/1801.110901.
62. Gray SJ, Campbell H, Marsh WJ, Carr AD, Newbold LS, Mallard RH, et al. EB. P 004. The epidemiology and surveillance of meningococcal disease in England and Wales (Page 41). The 11th European Meningococcal Group Meeting (EMGM) Congress 2011: Ljubljana, Slovenia, Abstract available at: <> [accessed 04.11.11]. http://emgm.eu/meetings/emgm2011/abstracts.pdf.
63. Fransen F., Heckenberg S.G.B., Hamstra H.J., Feller M., Boog C.J.P., van Putten J.P.M., et al. Naturally occurring lipid A mutants in Neisseria meningitidis from patients with invasive meningococcal disease are associated with reduced coagulopathy. PLoS Pathog 2009, 5(4):e1000396.
64. Fransen F., Hamstra H.J., Boog C.J., van Putten J.P., van den Dobbelsteen G.P., van der Ley P. The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease. Infect Immun 2010, 78(7):3177-3186.
65. Ala'aldeen D.A., Oldfield N.J., Bidmos F.A., Abouseada N.M., Ahmed N.W., Turner D.P., et al. Carriage of meningococci by university students, United Kingdom. Emerg Infect Dis 2011, 17(9):1762-1763.
66. Bidmos F.A., Neal K.R., Oldfield N.J., Turner D.P., Ala'Aldeen D.A., Bayliss C.D. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J Clin Microbiol 2011, 49(2):506-512.
67. Trotter C, Findlow H, Chadha H, Townsend K, Thompson D, Mabey L, et al. P 036. Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009 (pages 109-10). The 11th European Meningococcal Group Meeting (EMGM) Congress 2011: Ljubljana, Slovenia, Abstract available at: <> [accessed 04.11.11]. http://emgm.eu/meetings/emgm2011/abstracts.pdf.
68. Gasparini R., Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccine 2011, 7(2):170-182.
69. Granoff D, Pelton SI, Harrison LH. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: W.B. Saunders Company, in press.
70. Cohn A.C., MacNeil J.R., Harrison L.H., Hatcher C., Theodore J., Schmidt M., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010, 50(2):184-191.
71. Advisory Committee on Immunization Practices (ACIP) Updated recommendations for use of meningococcal conjugate vaccines, 2010. MMWR Morb Mortal Wkly Rep 2011, 60:72-76.
72. Advisory Committee on Immunization Practices (ACIP) Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease, 2011. MMWR Morb Mortal Wkly Rep 2011, 60:1018-1019.
73. MacNeil J.R., Cohn A.C., Zell E.R., Schmink S., Miller E., Clark T., et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J 2011, 30(6):451-455.
74. Castilla J., Vázquez J.A., Salcedo C., García Cenoz M., García Irure J.J., Torroba L., et al. B:2a:P1.5 meningococcal strains likely arisen from capsular switching event still spreading in Spain. J Clin Microbiol 2009, 47(2):463-465.
75. Mayer L.W., Reeves M.W., Al-Hamdan N., Sacchi C.T., Taha M.K., Ajello G.W., et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis 2002, 185(11):1596-1605.
76. Decosas J., Koama J.B. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2002, 2:763-765.
77. Harrison L.H., Shutt K.A., Schmink S.E., Marsh J.W., Harcourt B.H., Wang X., et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era-United States, 2000-2005. J Infect Dis 2010, 201(8):1208-1224.
78. Trotter C.L., Ramsay M.E., Gray S., Fox A., Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 2006, 6(10):616-617. [author reply 617-8].
79. Pollard A.J., Scheifele D. Meningococcal disease and vaccination in North America. J Paediatr Child Health 2001, 37(5):S20-S27.
80. Varughese P., Acres S. Meningococcal disease in Canada. Evolution of meningococcal disease 1987, 47-63. CRC Press, Inc., Boca Raton. N. Vedros (Ed.).
81. Watkins K.M., Deeks S.L., Medaglia A., Tsang R.S.W. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003. Can Commun Dis Rep 2006, 32(8):97-107.
82. Varughese P.V., Carter A.O. Meningococcal disease in Canada. Surveillance summary to 1987. Can Dis Wkly Rep 1989, 15(17):89-96.
83. National Advisory Committee on Immunization Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2009, 36(ACS-3):1-40.
84. Deeks S., et al. Surveillance of invasive meningococcal disease in Canada: 1995-1996. Can Commun Dis Rep 1997, 23(16):121-125.
85. Case definitions for communicable diseases under national surveillance. Can Commun Dis Rep 2009, 35(S2):1-128.
86. Scheifele D.W. IMPACT after 17 years: lessons learned about successful networking. Paediatr Child Health 2009, 14(1):33-35.
87. Parkinson A.J., Bruce M.G., Zulz T. International Circumpolar Surveillance: an Arctic network for the surveillance of infectious diseases. Emerg Infect Dis 2008, 14(1):18-24.
88. Publicly funded immunization programs in Canada - Routine schedule for infants and children including special programs and catch-up programs. 2011 July 7, 2011 [cited 2011 August 10]; Available at: http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php.
89. Bettinger J.A., Scheifele D.W., Le Saux N., Halperin S.A., Vaudry W., Tsang R., et al. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009, 28(3):220-224.
90. Bettinger J.A., Le Saux N., Scheifele D.W., Vaudry W., Halperin S.A., Bortolussi R., et al. The epidemiology of serogroup B meningococcal infections in Canada: IMPACT 2002-2009 [abstract]. Can J Infect Dis Med Microbiol 2010, 21(4):179. Abstract O10.
91. Bettinger J., Scheifele D., Le Saux N., Halperin S., Vaudry W., Bortolussi R., et al. Update on the incidence of meningococcal infections in Canada, IMPACT 2002-2009 [abstract]. Program and abstract guide of the 17th International Pathogenic Neisseria Conference 2010, Sep 11-16; Banff, AB. p. 95. Abstract P036.
92. Law D.K., Lorange M., Ringuette L., Dion R., Giguère M., Henderson A.M., et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol 2006, 44(8):2743-2749.
93. Le Saux N., Bettinger J.A., Wootton S., Halperin S.A., Vaudry W., Scheifele D.W., et al. Profile of serogroup Y meningococcal infections in Canada: implications for vaccine selection. For the members of the Canadian Immunization Monitoring Program, Active (IMPACT). Can J Infect Dis Med Microbiol 2009, 20(4):e130-e134.
94. Tsang R.S.W., Squires S.G., Zollinger W.D., Ashton F.E. Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada: January 1, 1999 to June 30, 2001. Can J Infect Dis 2002, 13(6):391-396.
95. Tsang R.S., Henderson A.M., Cameron M.L., Tyler S.D., Tyson S., Law D.K., et al. Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol 2007, 45(6):1753-1758.
96. Safadi M.A., Cintra O. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res 2010, 32(3):263-271.
97. Pan American Health Organization. Informe Regional de SIREVA II: Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores, 2010. OPS. Documentos Técnicos, Tecnologías Esenciales de Salud. Washington, DC, 2011: Pan American Health Organization, Available at: <>; 2011. http://new.paho.org/hq/index.php%3Foption=com_content%26task=blogcategory%26id=3609%26Itemid=3953.
98. Epidemiologic Surveillance Center (Brazil). Respiratory transmitted diseases, Available at: http://www.cve.saude.sp.gov.br/.
99. Ministry of Health. Meningococcal disease in Brazil, Available at: http://portal.saude.gov.br/portal/saude/area.cfm%3Fid_area=962.
100. Moraes J.C., Barata R.B. Meningococcal disease in São Paulo, Brazil, in the 20th century XX: epidemiological characteristics. Cad Saude Publica 2005, 21(5):1458-1471. [in Portuguese].
101. Lemos A.P., Brandaõ A.P., Gorla M.C., Paiva M.V., Simonsen V., Melles C.E., et al. Phenotypic characterization of Neisseria meningitidis strains isolated from invasive disease in Brazil from 1990 to 2001. J Med Microbiol 2006, 55(6):751-757.
102. Sacchi C.T., Fukasawa L.O., Gonçalves M.G., Salgado M.M., Shutt K.A., Carvalhanas T.R., et al. Incorporation of real-time PCR into routine public health surveillance of culture negative bacterial meningitis in São Paulo, Brazil. PLoS ONE 2011, 6(6):e20675.
103. Iser B.P., Lima H.C., De Moraes C., De Almeida R.P., Watanabe L.T., Alves S.L., et al. Outbreak of Neisseria meningitidis C in workers at a large food-processing plant in Brazil: challenges of controlling disease spread to the larger community. Epidemiol Infect 2011, 1-10. [Epub ahead of print] DOI:10.1017/S0950268811001610.
104. Argentinean Society of Pediatrics. Bacterial meningitis and meningococcal disease. Infectious Diseases National Committee, Available at: <>; 2011. http://www.sap.org.ar/staticfiles/comunicaciones/menin2008.pdf.
105. Efron A.M., Sorhouet C., Salcedo C., Abad R., Regueira M., Vázquez J.A. W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina. J Clin Microbiol 2009, 47(6):1979-1980.
106. Pírez M.C., Picón T., Galazka J., Rubio I., Montano A., Ferrari A.M., et al. Control de un brote epidémico de enfermedad meningocócica por N. meningitidis serogrupo B. Rev Med Uruguay 2004, 20(2):92-101.
107. Chile Ministry of Health. Epidemiologic Surveillance Department. Meningococcal disease situation, Available at: <>; 2011. http://epi.minsal.cl/epi/html/bolets/reportes/Meningitis/meningitis.pdf.
108. Agudelo C.I., Sanabria O.M., Ovalle M.V. Serogroup Y meningococcal disease, Colombia. Emerg Infect Dis 2008, 14:990-991.
109. Ministry of Health, Venezuela. Epidemiology, Available at: <> [July 2008]. http://www.mpps.gob.ve/ms/index.php.
110. Chacon-Cruz E., Sugerman D.E., Ginsberg M.M., Hopkins J., Hurtado-Montalvo J.A., Lopez-Viera J.L., et al. Surveillance for invasive meningococcal disease in children, US-Mexico border, 2005-2008. Emerg Infect Dis 2011, 17(3):543-546.
111. Pérez Rodríguez A., Dickinson F., Baly A., Martin R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem Inst Oswaldo Cruz, Rio de Janeiro 1999, 94:433-440.